Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Cash & Equivalents (2016 - 2025)

RedHill Biopharma has reported Cash & Equivalents over the past 15 years, most recently at $4.0 million for Q4 2025.

  • Quarterly Cash & Equivalents fell 13.99% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, down 13.99% year-over-year, with the annual reading at $4.0 million for FY2025, 13.99% down from the prior year.
  • Cash & Equivalents was $4.0 million for Q4 2025 at RedHill Biopharma, down from $4.6 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $76.0 million in Q1 2021 and troughed at $4.0 million in Q4 2025.
  • The 5-year median for Cash & Equivalents is $20.0 million (2022), against an average of $27.0 million.
  • Year-over-year, Cash & Equivalents surged 161.76% in 2021 and then plummeted 72.11% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $29.5 million in 2021, then crashed by 32.25% to $20.0 million in 2022, then plummeted by 72.11% to $5.6 million in 2023, then decreased by 17.09% to $4.6 million in 2024, then fell by 13.99% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Cash & Equivalents are $4.0 million (Q4 2025), $4.6 million (Q2 2025), and $4.6 million (Q4 2024).